Triple negative breast cancer (TNBC)/ basal-like breast cancer (BLBC) is a highly aggressive form of breast cancer prevalent in African-American (AA) women. We previously reported that a small molecule agonist ligand for the orphan nuclear receptor estrogen-related receptor beta (ERRβ or ESRRB) has growth inhibitory and anti-mitotic activity in TNBC cell lines. In this study, we evaluate the association of ESRRB mRNA, copy number levels, and protein expression with demographic, clinicopathological, and gene expression features in breast tumor clinical specimens.
INTRODUCTION
Breast cancer is the most commonly diagnosed cancer in women and is the number two cause of cancer-related death [1] . Breast cancer subtypes are predominantly classified by two methods: immunohistochemistry (IHC) or gene expression. IHC tests for three proteins: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor two (HER2), and based on the expression of these three receptors, patients are classified as having ER+, HER2 overexpressing, or triple negative breast cancer (TNBC). Patients who are diagnosed with TNBC are clinically defined as lacking ER, PR, and HER2 [2] . Gene expression profiling uses a 50-gene panel to determine if a breast cancer is one of 5 intrinsic, or Pam50 subtypes:
luminal A, luminal B, HER2-enriched, normal-like and basal-like (BLBC) [3, 4] . In clinic, TNBC and BLBC patients largely converge [5] . TNBC/BLBC is a biologically aggressive subtype of breast cancer with characteristic high genomic instability [6] . It is diagnosed more frequently in African-American (AA) women with much worse prognosis than Caucasian/White (CW) women [7] .
Since TNBC patients lack ER and HER2, they are unresponsive to ER and HER2-targeted therapies. Patients must instead be given systemic chemotherapy, which is accompanied by toxic side effects [8] . Due to the aggressive nature of TNBC, it is important to identify new prognostic marker genes capable of defining targets and conversely subtypes within TNBC. Historically, nuclear receptors (NR) have been great targets for cancer treatment, such as the ER in ER+ breast cancer. The NR superfamily consists of many members including orphan nuclear receptors (ONRs) [9] which are defined as lacking any known endogenous ligands. One ONR subgroup contains what are known as the estrogen related receptors (ERR), named for their resemblance to the ER, although they do not bind or respond to estrogen [9] . ERR beta (ESRRB, ERRβ), which is alternatively spliced, is one of the first discovered ONRs and is known to have important functions in development [10] . Our lab and others, have previously shown the function of ERRβ in cancer. Our 2016 publication showed that BLBC patients with high ESRRB mRNA expression have significantly improved distant-metastases free, and recurrence-free survival in comparison to patients with low expression [11] . Previous publications have shown that BLBC patients overall have significantly lower ESRRB mRNA expression in comparison to other breast cancer subtypes [12, 13] .
The goal of the present study is to: (1) define ESRRB expression levels in breast cancer, specifically in BLBC and TNBC; (2) determine how DNA copy number and protein levels are modulated in various data sets; (3) characterize clinical correlations found in breast cancer. We show that ESRRB mRNA expression is significantly lower in BLBC/ TNBC patients and that there is no observed decrease in DNA copy number.
ERRβ splice variants have differential transcription factor activity in TNBC cell lines.
Lastly, we also show that ERRβ splice variant protein levels are different in breast cancer patient samples depending on the IHC subtype. HER2 and TNBC patients have similar ERRβ protein expression and cellular localization vs. ER+ patients. Our study supports further investigation into the establishment of ERRβ as a TNBC/BLBC therapeutic target or prognostic marker, and as a tool to provide more insights into this aggressive cancer and its mechanism of progression.
Materials and Methods

In silico analyses
RNA-sequencing (RNAseq) data was obtained from two publically-available datasets sets: the Sweden Cancerome Analysis Network -Breast (SCAN-B) [14, 15] and The Cancer Genome Atlas (TCGA) [16] . Gene expression profiles of GSE96058 (Table S1 ). Pathway and represented disease analyses were performed on overexpressed DEGs using KEGG pathway analysis [17, 18] .
For SCAN-B data, cox regression was used to determine correlations between ESRRB expression and clinical characteristics. For promoter analysis, Bioconductor was used to isolate DEGs found within annotated genome UCSC, hg19 and search the promoter region of these genes, -4000 to +500 bp from the transcription start site for enriched short, ungapped, redundant sequences of up to 8 base pairs using Discriminative Regular Expression Motif Elicitation (DREME, [19] BT549 cells were cultured in IMEM with 10% FBS and 10 µg/mL insulin (purchased from Life Technologies, Grand Island, NY).
Plasmids and transfection
The psG5 empty vector, ERRβsf (murine ERRβ, >90% homology to human ERRβ, Addgene #52188), ERRβ2 (Addgene #52186), and ERRβ-∆10 (Addgene #52187) constructs have all been published previously [11, 23] . The ERRE-luciferase (Addgene #37851) and p21-luciferase (Addgene #21723) have been previously described [23] . Plasmids were introduced using Mirus TransIT-X2 Dynamic Delivery System (Mirus Bio LLC; MIR600Q) according to manufacturer's instructions.
Dual-luciferase promoter-reporter assays
Cells were seeded into 24-well plastic tissue culture dishes at 150,000 cells per well on day 0. On day 1, cells were transfected using 500 ng DNA/ well (137 ng receptor; 360 ng luciferase reporter plasmid; 3 ng Renilla control) for 24 hours. On day 2, media containing the transfection complexes was removed and fresh media was added to the cells. On day 3, at 48 hours, cells were harvested for luciferase assay (https://www.promega.com/prod ucts/reporter-assays-and-transfection/reporterassays/dual_luciferase-reporter-assay-system/) according to the manufacturer's instructions. Luciferase activity was normalized to Renilla. All experiments were performed 3-5 times.
Western blotting and antibodies
Lysate collected for dual-luciferase activity assay were run on 4-12% poly acrylamide gels using electrophoresis for 90 minutes. After protein was transferred to nitrocellulose membranes, the membranes were blocked for one hour in 5% nonfat dry milk in Tris-Buffered Saline with Tween-20 (TBST) and probed overnight at 4°C with ERRβ #PP-H6707-00 (cl.07) 1:500. All membranes were then re-probed with loading control β -tubulin at 1:10:000 for 1 hour at room temperature or overnight at 4°C.
Horseradish peroxidase enzyme-conjugated anti-mouse whole immunoglobulin (IgG) secondary antibody (GE #NXA931 Buckinghamshire, U.K.) was used the following day at 1:5000 for 1 hour at room temperature. The membranes were then imaged for enhanced chemiluminescence (ECL, Denville Scientific, Holliston, MA) on the Amersham Imager 600 (GE Life Sciences).
Image analysis and statistical analysis of in vitro work
Images and figures were composed using Adobe Photoshop, Illustrator and InDesign. FIJI was used to perform densitometry on imaged blots. Statistical analyses of dual-luciferase activity assay and western blot densitometry were done using PRISM 8.0 (Graphpad, San Diego, CA).
Invasive Ductal Carcinoma Breast Cancer TMA series
The were treated with 3% hydrogen peroxide, avidin/biotin blocking, and 10% normal goat serum and independently exposed to primary antibodies for ERRβsf-cl .07, 1:150, 1:240 (R&D systems, #PP-H6707-00) and ERRβ2-cl .05, 1:150 (R&D systems, #PP-H6705-00) for 1 hour at room temperature. Slides were exposed to appropriate biotinconjugated secondary antibodies (Vector Labs), Vectastain ABC reagent and DAB chromagen (Dako). Slides were counterstained with Hematoxylin (Fisher, Harris
Modified Hematoxylin), blued in 1% ammonium hydroxide, dehydrated, and mounted with Acrymount. Control tissues with the primary antibody omitted were used as negative controls.
Scanning and Analysis using Vectra3
Stained slides were scanned using the Vectra3 Multi-Spectral Imaging Microscope with 
Statistical analysis of tissue microarray data
To prepare for statistical analysis, individual cores were manually examined and matched to their corresponding coordinates defined by Vecta3 software. Any cores missing more that 50% of tissue due to adipose tissue or folding were omitted from final analysis. The two cores from each patient were individually scored then averaged to determining the 50 scores per TMA slide used in the analyses.
ERRβ-clone 07 (recognizes ERRβ2), ERRβ-clone 05 (recognizes ERRβsf), and their ratio, as well as demographic variables were summarized by using mean (standard deviation, sd) and median (interquartile range, IQR) for continuous variables and frequency and percentage for categorical variables. Kruskal-Wallis tests were used to test whether median ERRβ2 and ERRβsf expression, and their ratio, were significantly different among the three IHC receptor subtypes. In order to assess whether the expression of each isoform was significantly different among the three IHC subtypes while considering lymph node status, race, and age, and if there was any interaction between IHC subtype and demographic variables, we first made a logit transformation of ERRβ− clone 07 and ERRβ− clone 05 which achieved approximate normality. Then two-way ANOVA was used for analysis following ANOVA procedure. If a significant difference was observed, pairwise comparisons were performed by Dwass, Steel, Critchlow-Fligner multiple comparison procedure (DSCF).
Nuclear staining and cytoplasmic staining were summarized by IHC subtype using mean (sd) and median (IQR). Spearman's correlation coefficient was calculated to measure the association between the nuclear and cytoplasmic staining in each IHC subtype.
All tests were two-sided at a significant level 0.05. No method had been used for adjusting multiple comparisons. All analyses were performed using SAS 9.4 and Rstudio (Version 0.99.902) software.
RESULTS
Low ESRRB mRNA expression is associated with shorter overall survival
We previously published that high expression of ESRRB mRNA is associated with improved recurrence-free and distant-metastasis free survival in a merged cohort of BLBC patients from multiple independent studies [11, 24] . Here, we analyzed the association of ESRRB mRNA expression with overall survival by analyzing Illumina HT 12 gene array data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) study [25] . Importantly, patients selected for this analysis were systemically untreated, providing a more compelling link between ESRRB expression and clinical outcome that is not confounded by treatment effect. We found that low ESRRB expression (defined as below median) is associated with significantly shorter overall survival (OS) only in BLBC patients ( Fig. 1 ).
ESRRB mRNA expression levels are significantly decreased in BLBC and TNBC, but not associated with age, grade, or lymph node status
We used two large, publicly-available RNAseq data sets -SCAN-B [14, 15] and
The Cancer Genome Atlas (TCGA) [16] -to analyze ESRRB mRNA expression in association with demographic, clinicopathologic, and gene expression features. ESRRB expression as FPKM was measured in both data sets in patients stratified by either IHC or Pam50 breast cancer subtypes for analysis ( Fig. 2) . In SCAN-B, ESRRB expression was significantly lower in BLBC patients compared to luminal A and normal-like patients ( Fig. 2a ). ESRRB expression was also significantly lower in TNBC patients vs. ER+ and ER+/HER2+ patients (Fig. 2b) . In TCGA data, we confirmed the previously published findings of Garattini, et al. [13] and found that BLBC patients had significantly lower ESRRB expression compared to luminal A patients ( Fig. 2c ). Like the SCANB cohort, TCGA-TNBC patients also had significantly lower ESRRB expression compared to ER+ and ER+/HER2+ patients ( Fig. 2d ).
SCAN-B is a 3273-patient data set collected in Sweden starting in 2010 [14, 15] .
Biospecimens were collected and RNAseq was performed on biopsy cores as previously described [14] . Comprehensive clinical and demographic information was also collected, allowing for analysis of ESRRB association with these data for both the Pam50 and IHC subtypes. Analysis of Pam50 subtype revealed BLBC patients were significantly younger than luminal A, luminal B, and HER2 patients (Fig. S1a ), a characteristic commonly found in BLBC patients, while analysis by IHC subtype showed that HER2 patients were significantly younger that ER+ patients ( Fig. S1b ).
We also assessed the correlation between ESRRB high and low mRNA expression and clinical characteristics. Across the entire SCAN-B cohort, there was a weak but statistically significant positive correlation between estrogen receptor (ESR1) and ESRRB mRNA expression (p = 8.1 e-05, Fig. 2e ). There was no significant correlation between ESRRB expression and age ( Fig. 2f ). Filtered data sets were split into tertiles with the top third considered ESRRB "high" expression and the lower third considered "low" expression. Analysis within the Pam50 and IHC subtypes showed that there was no significant difference in age between ESRRB high and low patients within 
ESRRB does not have copy number loss in TNBC
Next, we sought to determine if the observed decrease in ESRRB mRNA expression found in TNBC/BLBC may be due to copy number loss. We approached this by analyzing an independent, 106-patient cohort of Caucasian (CW) and African American (AA) patients with TNBC and non TNBC (NTN) using array comparative genomic hybridization (aCGH) as previously described by Sugita, et al [22] . ESRRB copy number was calculated and defined as deletion, loss, gain, or amplification, and demographic information was analyzed for associations with ESRRB copy number changes ( Fig. S2a-e ). Fisher's exact test showed that in our cohort, patients with TNBC had significantly higher grade than non-triple negative (NTN) patients at diagnosis (p < 0.0001), indicating that our cohort is representative of the TNBC population (Fig. 3a ).
There were no significant differences observed between CW and AA patients with TNBC and NTN in relation to the total number of copy number alterations. However, > 75% of all patients showed copy number gain rather than loss at the ESRRB locus, 14q24.3 (Fig. 3b ).
Since self-reported race and ethnicity data are not always concordant with genotyping analyses, we also assessed ancestry informative markers (AIMs) and the distribution of ESRRB copy number in a small subset of our cohort [25, 27] . This 20patient subset included 6 TNBC patients and 14 NTN patients. Principal component analysis (PCA) of 3000 AIMs overlaid with self-reported ethnicity of our cases showed separation of distinct ancestral populations [22] when merged with two populations from the 1000 Genomes Project: African descent (AFR) and ad mixed American (AMR) (Fig. 3c) . The mean rank for ESRRB was markedly lower in the AA, but there was no statistically significant difference in the average ESRRB copy number in breast tumors from the AA women (clustered with the AFR group) versus the CW (clustered with the AMR group) ( Fig. 3d ).
Differentially expressed genes in ESRRB high versus ESRRB low patients
We next identified DEGs in ESRRB mRNA high versus low patients to determine what other genes are co-modulated with ESRRB expression. First, we compared ESRRB high and low patients (upper and lower tertiles, respectively) and assessed genes that were high in ESRRB-high patients (left/ pink) and low in ESRRB-high patients (right/ purple) (≥2-fold up-or down-regulated, p < 0.05, Fig. 4a-d ; Table S1 ).
We determined the overlap of DEGs between data sets and between BLBC and TNBC, finding the most overlap within datasets (Fig. 4e, Fig. S3a, b) . Prior studies report that greater than 80% of TNBC patients are also BLBC [5] and our analysis of the SCAN-B
and TCGA data sets shows a similar overlap (Fig. S3c,d) . KEGG pathway analysis [17, 18] found enrichment of genes associated with neuroactive ligand-receptor interaction (fold change (Table 1) .
ERRβ isoform transcription factor activity differs across cellular models of TNBC molecular subtypes
A key challenge in defining bona fide ESRRB target genes amongst DEGs from high dimensional data sets is that ERRβ, at the protein level, is expressed as at least three distinct isoforms: ERRβsf, ERRβ2, ERRβ-Δ10 [30, 31] . These isoforms are produced via alternative splicing in which a genetic alteration at intron-exon boundaries, or splice sites, are altered at the mRNA level resulting in different proteins [32] . Two of these isoforms -ERRβsf and ERRβ2 -have opposing functions in regulating cell cycle progression [11] , while less is known about ERRβ-Δ10 due to a lack of validated antibodies to detect this isoform at the protein level [33] . We first established basal level of two ERRβ isoforms -ERRβ2 and ERRβsf -in a panel of TNBC cell lines reflective of diverse TNBC subtypes. TNBC subtypes were initially defined as a step to further personalize medicine. There are 6 distinct TNBC subtypes based on gene expression and ontology [34, 35] . Cell lines representing 5 of the 6 subtypes, as well as nontransformed mammary epithelial cells MCF10A and estrogen-receptor positive cells MCF7, were probed for ERRβ2 and ERRβsf using two monoclonal antibodies we have previously characterized as selective for each isoform [11, 23] . TNBC cell lines had a trend toward lower ERRβ protein levels in comparison to the MCF10As and MCF7s
( Fig. 5a -c, Figure S4a , b). HCC1806s (basal-like 2, BL2) had the lowest ERRβ2:ERRβsf ratio while MDA-MB-453s (luminal androgen receptor, LAR) had the highest ratio, though these differences did not reach statistical significance. Consistent with this, assessment of TNBC subtypes at the mRNA level in SCAN-B tumor also showed no significant differences in ESRRB expression between the subtypes (Fig. S4c ). Analysis of publicly available gene expression data in cell lines showed similar ERRβ2 mRNA expression ( Figure S4d, e ).
To measure transcription factor function of ERRβ isoforms, we overexpressed cDNAs for each isoform in three different TNBC cell lines and measured their ability to induce transcription from heterologous promoter-reporter constructs. The three cell lines used were HCC1806, MDA-MB-453, and BT549, representing 3 of 6 TNBC subtypes [34] . The promoter-reporter constructs contained sequences corresponding to 2 established ERRβ response elements: estrogen related response element (ERRE, TNAAGGTCA) [36, 37] and specificity-protein-1 (SP1, (G/T)GGGCGG(G/A)(G/A)(C/T))
[38] (Figure 5d ) . SP1 was also one of the top motifs identified in the BLBC subtype from the SCAN-B data set (Table 1 ). In HCC1806 (BL2) cells, there was significantly higher activity of both the ERRE and SP1 response elements induced by all three splice variants in comparison to empty vector. ERRβsf had significantly higher activity on the ERRE than ERRβ2 or ERRβ-Δ10, while ERRβ-Δ10 had significantly higher activity on the SP1 response element than ERRβsf or ERRβ2. In MDA-MB-453 (LAR) cells,
ERRβsf had significantly higher activity on both the ERRE and SP1 response elements, while ERRβ-Δ10 had significantly higher activity on SP1 in comparison to empty vector.
In BT549 (mesenchymal-like, ML) cells, ERRβsf and ERRβ-Δ10 had significantly higher activity on both the ERRE and SP1 response elements in comparison to empty vector.
For both MDA-MB-453s and BT549s, ERRβ2 had no significant transcription factor activity on either ERRE or SP1. Western blot analysis confirmed overexpression of ERRβ isoforms in transfected cells ( Fig. 5e-g) . These data suggest that patterns of ERRβ isoform transcription factor activity may differ between basal-like and other TNBC molecular subtypes.
ERRβ isoform expression in breast tumor tissue varies by IHC subtype
We next assessed the protein expression of ERRβsf and ERRβ2 isoforms in patient tissues from a 150-patient TMA assembled by the HTSR at Georgetown University Medical Center's LCCC. The TMA series consists of 50 invasive ductal carcinoma breast cancer patients each diagnosed with ER+, HER2 overexpressing, and TNBC IHC subtypes, with corresponding demographic and clinical information (race, pathological stage, age, treatment, Table 2 ). Post antibody optimization, consecutive sections of the TMA were stained for 1 of 2 antibodies: ERRβ-clone 05 (recognizes ERRβsf) or ERRβ-clone 07 (recognizes ERRβ2). Staining was quantified in a semiautomated fashion and nuclear versus cytoplasmic staining were differentiated using the Vectra3 Multi-Spectral Imaging Microscope. (Fig.6a-c) . Representative image show the differential staining of the two antibodies ( Fig. 6d ). Statistical analyses were performed to determine the relationship of each isoform with lymph node status, race, and age.
The median of ERRβ2, but not ERRβsf, expression was significantly different amongst the three IHC receptor subtypes: ER+, HER2, TNBC (p = 0.016). Post hoc analysis showed that ERRβ2 was significantly different between ER+ and HER2 patients (p = 0.017, Figure 7a , Table S2 .1). Median ERRβsf : ERRβ2 expression ratio was lowest in TNBC subtypes (indicating lower ERRβ2 or higher ERRβsf expression), however this ratio was not statistically significantly different amongst the three IHC receptor subtypes (Figure 7b ).
We next assessed statistical interactions and main effects of three variables: IHC (p = 0.024) or difference in ERRβ2 expression amongst the different races (Fig. 7c , Table S3 ). Follow-up post-hoc Kruskal-Wallis found that the ERRβ2 median was significantly different amongst the three IHC subtypes in AA patients (p = 0.0312, Figure   7d ). Further pairwise comparisons with DSCF method showed this observed difference was between ER+ and TNBC patients (p = 0.0212, Figure 7b, d ).
There were no significant statistical interactions between the IHC subtypes and lymph node status or age that affected ERRβsf status, however we did see significant interaction effect with race (p = 0.009) indicating differential ERRβsf expression within the 5 races between the 3 IHC subtypes (Table S3 , Fig. 7e ). This significant interaction was followed up with a Kruskal-Wallis post hoc analysis which showed that median ERRβsf expression was significantly different among 5 races in the HER2 IHC receptor subtype (p = 0.0102). Follow-up pairwise comparisons showed that this significant difference was between AA and CW patients (p = 0.0282, Figure 7f ).
We next analyzed the subcellular localization of ERRβsf and ERRβ2 isoforms amongst the different IHC subtypes. Previous studies have shown that ERRβsf and ERRβ2 have different localization and functions within cells [11] , with ERRβsf predominantly nuclear and ERRβ2 expressed in both the nucleus and cytoplasm.
ERRβ2 had higher cytoplasmic vs. nuclear staining in ER+ patients compared to HER2 and TNBC patients, while ERRβsf had both nuclear and cytoplasmic staining in all three IHC subtypes (Fig. 8a, 8b , Figure 8c ).
DISCUSSION
In this study, we characterize ONR ESRRB/ERRβ copy number and expression and its clinical correlations in breast cancer. Patients with low ESRRB mRNA expression have significantly shorter overall survival. ESRRB mRNA expression is significantly lower in TNBC/BLBC vs. other breast cancer subtypes, but not significantly associated with age, lymph node status, or grade. In an independent dataset, we find no evidence of ESRRB copy number loss in TNBC patients, suggesting that reduced mRNA expression is driven by other mechanisms. We further find that ESRRB expression is correlated with that of genes associated with neuroactive ligand-receptor interaction, metabolic pathways, and deafness, and that these genes contain G/C-rich transcription factor binding motifs. We show that the ESRRB message, which is alternatively spliced into three distinct isoforms, leads to different isoform transcription factor activity in TNBC cell lines that are characterized as basal-like vs. the mesenchymal or luminal androgen receptor subtype. Finally, we show in clinical samples that the ERRβ2 and ERRβsf isoforms are broadly expressed at the protein level.
We found that the loss of ESRRB mRNA in TNBC/BLBC patients was not due to a loss of copy number, and in fact there was a gain in ESRRB copy number in all breast cancer subtypes. Though the copy number gain was not significant, it does suggest that there is a mechanistic variance occurring during transcription of this gene in breast cancer patients that drives the loss of mRNA that is consistently and significantly observed especially in TNBC/BLBC. While our ancestrality marker results were not significant, in the subset, which had a small number of patients, we saw a trend toward reduced ESRRB copy number in AA versus CW patients which aligned with 1000 genome projects defined AFR and AMR patients, respectively. This addresses a clinical diagnosis issue frequently encountered in which demographic information is misreported [39] . In this case, we looked at self-reported race in comparison to refined race and ethnic information from genotyping, and saw a difference in copy number that was not seen with only the self-reported race. Our results suggest that there is value to the addition of ancestrality markers to future analyses would add more insight.
When looking at transcription factor activity we found that the three known splice variants ERRβsf, ERRβ2, ERRβ−Δ10 when exogenously expressed, have differential activity on known ESRRB response elements. In basal-like TNBC cell line, BL2, ERRβsf had higher activity on the ERRE while ERRβ−Δ10 had higher activity on the sp1 response element. Meanwhile in LAR and ML TNBC cell lines, ERRβsf and ERRβ−Δ10 had higher activity on both response elements, while ERRβ2 had no change in activity.
The LAR and ML subtypes are consistent with our previous publication in which we showed that in a ER+ setting ERRβsf has higher activity on the ERRE while ERRβ2
shows no change in activity [11] . The difference in activity may be explained by the differing C-terminus of the splice variants. While all three isoforms share exons 3 -9,
ERRβsf is truncated at exon 9, ERRβ2 has exon 10 and part of 11 and ERRβ−Δ10 skips This is the first reported comparative quantification of ERRβsf and ERRβ2 protein expression in IHC breast cancer subtypes. Our 150-patient TMA revealed that in all three IHC subtypes (ER+, HER2, TNBC) ERRβ2 is expressed in higher quantities than ERRβsf. We established that ERRβ2 was significantly different between ER+ and HER2 patients, and that the ratio of ERRβ2:ERRβsf was lower in TNBC patients that it was in ER+ or HER2 patients. Though this difference was not statistically significant, it did suggest that in the more aggressive breast cancer subtype there is an increase in the ERRβsf splice variant. Our previous publications have led to the hypothesis that ERRβ specific -ligand-mediated mitotic arrest is due to the ERRβ2 splice variant, and that the loss of this splice variant is an effect of the malignant transformation associated with TNBC/BLBC [11] .
We have previously published that in breast cancer cell lines ERRβ2 localizes to the cytoplasm and centrosomes in the nucleus while ERRβsf localizes in the nucleus [11] . We further looked at this localization to see if there were differences amongst the three IHC subtypes. We established that while in ER+ tumors there was a positive correlation between nuclear and cytoplasmic staining for ERRβ2 and ERRβsf, both HER2 and TNBC -clinically aggressive subtypes -showed a positive correlation for b.
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